Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity. (Record no. 29944652)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02236 a2200673 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518052308.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202006s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1538-8514 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1158/1535-7163.MCT-18-0048 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Bartz, René |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20200609 |
| 245 00 - TITLE STATEMENT | |
| Title | Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Molecular cancer therapeutics |
| Date of publication, distribution, etc. | 10 2019 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1832-1843 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Animals |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | pharmacology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Line, Tumor |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cholestyramine Resin |
| General subdivision | pharmacology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gene Expression Regulation |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Ileum |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Liver |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mice |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mice, Inbred BALB C |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | NIH 3T3 Cells |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Receptor, Fibroblast Growth Factor, Type 4 |
| General subdivision | immunology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Signal Transduction |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Sorafenib |
| General subdivision | pharmacology |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fukuchi, Keisuke |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ohtsuka, Toshiaki |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lange, Tanja |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gruner, Katrin |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Watanabe, Ichiro |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hayashi, Shinko |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Oda, Yoko |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kawaida, Reimi |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Komori, Hironobu |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kashimoto, Yoshinori |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wirtz, Peter |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mayer, Jan-Peter A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Redondo-Müller, Mauricio |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Saito, Shuntaro |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Takahashi, Mizuki |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hanzawa, Hiroyuki |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Imai, Emi |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Martinez, Alberto |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hanai, Masaharu |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Häussinger, Dieter |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Chapman, Roger W |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Agatsuma, Toshinori |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bange, Johannes |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Abraham, Reimar |
| 773 0# - HOST ITEM ENTRY | |
| Title | Molecular cancer therapeutics |
| Related parts | vol. 18 |
| -- | no. 10 |
| -- | p. 1832-1843 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1158/1535-7163.MCT-18-0048">https://doi.org/10.1158/1535-7163.MCT-18-0048</a> |
| Public note | Available from publisher's website |
No items available.